济民健康
(603222)
| 流通市值：51.25亿 | | | 总市值：51.25亿 |
| 流通股本：5.25亿 | | | 总股本：5.25亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 544,718,299.64 | 366,449,449 | 181,021,832.06 | 775,728,783.82 |
| 营业收入 | 544,718,299.64 | 366,449,449 | 181,021,832.06 | 775,728,783.82 |
| 二、营业总成本 | 592,923,784.23 | 397,731,310.44 | 193,701,654.9 | 838,763,292.43 |
| 营业成本 | 348,045,819.3 | 231,349,638.74 | 112,899,698.69 | 486,265,705.33 |
| 税金及附加 | 9,574,899.43 | 6,737,022.5 | 2,577,520.95 | 12,072,346.61 |
| 销售费用 | 104,068,515.79 | 72,014,066.32 | 35,722,853.68 | 162,741,569.96 |
| 管理费用 | 84,572,171.24 | 57,297,306.04 | 26,169,153.97 | 118,291,817.19 |
| 研发费用 | 30,535,831.43 | 19,872,078.24 | 11,063,802.31 | 41,606,879 |
| 财务费用 | 16,126,547.04 | 10,461,198.6 | 5,268,625.3 | 17,784,974.34 |
| 其中:利息费用 | 17,930,270.81 | 11,733,242.8 | 5,927,978.64 | 21,029,105.73 |
| 其中:利息收入 | 2,177,819.32 | 1,440,886.11 | 668,412.84 | 2,846,905.09 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -7,309.28 | -6,743.31 | -3,627.14 | 1,395,733.01 |
| 资产处置收益 | -68,690.52 | -68,690.52 | - | -4,058,171.07 |
| 资产减值损失(新) | -35,263,447.19 | -23,564,668.37 | -2,592,460.37 | -9,860,824.61 |
| 信用减值损失(新) | -9,561,131.3 | -5,587,754.58 | -481,747.64 | 2,741,587.86 |
| 其他收益 | 3,275,608.65 | 2,078,660.05 | 1,033,503.84 | 9,235,999.29 |
| 四、营业利润 | -89,830,454.23 | -58,431,058.17 | -14,724,154.15 | -63,580,184.13 |
| 加:营业外收入 | 1,955,358.43 | 1,916,758.95 | 137,344.97 | 3,334,306.03 |
| 减:营业外支出 | 2,832,970.95 | 1,112,349.75 | 252,815.06 | 6,209,311.57 |
| 五、利润总额 | -90,708,066.75 | -57,626,648.97 | -14,839,624.24 | -66,455,189.67 |
| 减:所得税费用 | -15,338,809.84 | -7,907,680.02 | -3,141,947.7 | -10,328,114.12 |
| 六、净利润 | -75,369,256.91 | -49,718,968.95 | -11,697,676.54 | -56,127,075.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -75,369,256.91 | -49,718,968.95 | -11,697,676.54 | -56,127,075.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -77,150,360.1 | -52,695,852.83 | -13,636,453.43 | -59,711,716.5 |
| 少数股东损益 | 1,781,103.19 | 2,976,883.88 | 1,938,776.89 | 3,584,640.95 |
| 扣除非经常损益后的净利润 | -76,535,346.56 | -53,201,025.17 | -13,549,130.43 | -58,691,795.59 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.15 | -0.1 | -0.03 | -0.11 |
| (二)稀释每股收益 | -0.15 | -0.1 | -0.03 | -0.11 |
| 八、其他综合收益 | 7,332,986.44 | 7,888,484.03 | 2,476,778.89 | -3,224,364.3 |
| 归属于母公司股东的其他综合收益 | 7,332,986.44 | 7,888,484.03 | 2,476,778.89 | -3,224,364.3 |
| 九、综合收益总额 | -68,036,270.47 | -41,830,484.92 | -9,220,897.65 | -59,351,439.85 |
| 归属于母公司股东的综合收益总额 | -69,817,373.66 | -44,807,368.8 | -11,159,674.54 | -62,936,080.8 |
| 归属于少数股东的综合收益总额 | 1,781,103.19 | 2,976,883.88 | 1,938,776.89 | 3,584,640.95 |
| 公告日期 | 2025-10-31 | 2025-08-21 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |